Lifeline™ vascular grafts are built using Cytograft’s patented sheet-based tissue engineering technology.
Lifeline™ is a living blood vessel and does not contain any synthetic materials. Since the vessel is assembled exclusively from the patient’s own cells, the risk of tissue rejection, infection, or disease transmission is minimal.
Lifeline™ is a promising technology that will be used as a coronary graft for coronary bypass candidates, as a peripheral graft for lower limb amputation candidates or as an arterio-venous shunt for hemodialysis patients.
Cytograft has built a state of the art production facility in Novato, California to support clinical trials.